SPIB is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the PI3K‐AKT pathway

Although the clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one‐third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Takagi, Yusuke, Shimada, Kazuyuki, Shimada, Satoko, Sakamoto, Akihiko, Naoe, Tomoki, Nakamura, Shigeo, Hayakawa, Fumihiko, Tomita, Akihiro, Kiyoi, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021043/
https://www.ncbi.nlm.nih.gov/pubmed/27348272
http://dx.doi.org/10.1111/cas.13001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021043/
https://www.ncbi.nlm.nih.gov/pubmed/27348272
http://dx.doi.org/10.1111/cas.13001

Ejemplares similares